

Pharmacokinetic effects of a single-dose nutritional ketone ester supplement on brain ketone and glucose metabolism in alcohol use disorder – a pilot study

- 1 Xinyi Li¹, Anthony J. Young², Lais S. Pereira-Rufino¹, Zhenhao Shi¹, Juliana Byanyima¹,
- 2 Sianneh Vesslee¹, Rishika Reddy¹, Timothy Pond¹, Mark Elliott², Ravinder Reddy², Robert K.
- 3 Doot², Jan-Willem van der Veen³, Henry R. Kranzler¹, Ravi Prakash Reddy Nanga², Jacob G.
- 4 Dubroff², Corinde E. Wiers¹
- 5 ¹Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine,
- 6 Department of Psychiatry, Philadelphia, PA
- ²University of Pennsylvania Perelman School of Medicine, Department of Radiology, Philadelphia,
- 8 PA

13

- 9 ³National Institute on Mental Health, National Institutes of Health, 10 Center Drive, Bethesda, MD
- 10 * Correspondence:
- 11 Corinde E. Wiers, Ph.D.
- 12 corinde.wiers@pennmedicine.upenn.edu
- 14 **Keywords:** beta-hydroxybutyrate, brain energetics, ketogenic diet, krebs cycle, metabolism,
- 15 nutritional supplement

Abstract

17

- 18 **Introduction:** Acute alcohol intake decreases brain glucose metabolism and increases brain uptake of
- 19 acetate, a metabolite of alcohol. Individuals with alcohol use disorder (AUD) show elevated brain
- acetate metabolism at the expense of glucose, a shift in energy utilization that persists beyond acute
- 21 intoxication. We recently reported that nutritional ketosis and administration of ketone bodies as an
- 22 alternative energy source to glucose reduce alcohol withdrawal severity and alcohol craving in AUD.
- However, the regional effects of nutritional ketosis on brain ketone (beta-hydroxybutyrate [BHB]) and
- 24 glucose metabolism have not been studied in AUD.
- 25 **Methods**: Five participants with AUD underwent two magnetic resonance imaging (MRI) sessions and
- 26 4 participants with AUD underwent two positron emission tomography (PET) sessions with ¹⁸F-
- 27 fluorodeoxyglucose. All participants completed one session without KE intervention and one session
- during which they consumed 395 mg/kg (R)-3-hydroxybutyl (R)-3-hydroxybutyrate Ketone Ester (KE)
- 29 intervention (TdeltaS Global Inc.) before the scan. The order of the sessions was randomized. For the
- 30 PET cohort, blood glucose and ketone levels were assessed and voxel-wise maps of the cerebral
- 31 metabolic rate of glucose (CMRglc) were computed at each session. For the MRI cohort, brain anterior
- 32 cingulate BHB levels were assessed using magnetic resonance spectroscopy.

Results

33

45

- A single dose of KE elevated blood BHB and anterior cingulate BHB levels compared to baseline.
- 35 Moreover, blood glucose levels were lower with KE than baseline, and whole-brain CMRglc decreased
- 36 by 17%. The largest KE-induced CMRglc reductions were in the frontal, occipital, cortex, and anterior
- 37 cingulate cortices.

38 Conclusion

- 39 These findings provide preliminary evidence that KE administration elevates ketone and reduces brain
- 40 glucose metabolism in humans, consistent with a shift from glucose to ketones as a brain energy source.
- 41 Average reductions in CMRglc of 17% are similar to global average reductions documented with
- 42 administration of 0.25-0.5 g/kg of alcohol. Documenting the clinical and neurometabolic effects of
- 43 nutritional ketosis will yield fundamental knowledge as to its potential beneficial effects as a treatment
- 44 for AUD and its underlying neural mechanisms.

1 Introduction

- 47 Alcohol use disorder (AUD) is a chronic, relapsing condition that is associated with substantially
- 48 elevated risk of neurocognitive impairments, co-occurring medical and psychiatric disorders, and
- 49 mortality. In the United States, approximately 95,000 alcohol-related deaths were reported annually
- between 2011 and 2015, making alcohol the third-leading cause of preventable death (Esser et al.
- 51 2020). However, only 1.6 % of patients with AUD receive FDA-approved medications to treat the
- disorder (Han et al. 2021) and available treatments are not efficacious for all patients (Campbell et al.
- 53 2018).

- 54 Improving brain energetics in individuals with AUD is a novel potential therapeutic intervention
- 55 (Mahajan et al. 2021; Wiers et al. 2021). Acute alcohol intake increases the utilization of acetate, a
- metabolite of alcohol, at the expense of glucose utilization (Volkow et al. 2013; Volkow et al. 2017).
- 57 In individuals with AUD, low brain glucose and high acetate metabolism persist beyond acute
- intoxication (Jiang et al. 2013; Tomasi et al. 2019; Volkow et al. 2017; Wang et al. 2013).
- 59 Deprivation of acetate as an energy source during abstinence may contribute to alcohol withdrawal
- signs and symptoms, alcohol craving, and relapse in individuals with AUD (Mahajan et al. 2021).
- Ketone bodies [β-hydroxybutyrate (BHB)], acetoacetate, and acetone) resemble acetate and may
- provide an alternative to it as an energy source in the brain (Courchesne-Loyer et al. 2017). Previous
- work in our laboratory has demonstrated the efficacy of a high-fat, low-carbohydrate ketogenic
- dietary intervention in reducing alcohol withdrawal severity and alcohol craving in AUD patients
- undergoing alcohol detoxification (Wiers et al. 2021). These findings are concordant with preclinical
- models showing that a ketogenic diet reduces both the signs of alcohol withdrawal (Bornebusch et al.
- 67 2021; Dencker et al. 2018; Tanabe et al. 2021) and alcohol self-administration (Blanco-Gandía et al.
- 68 2021; Wiers et al. 2021).
- 69 Given the restrictive nature of the KD and poor patient adherence to the strict dietary regimen (Ye et
- al. 2015), exogenous BHB ketone supplementation provides an easier alternative to elevate plasma
- ketone bodies (Stubbs et al. 2017). Exogenous ketone supplementation is a well-tolerated
- 72 intervention that may pose various health benefits: ketones improved cognition in preclinical and
- clinical models of Alzheimer's Disease (Kashiwaya et al. 2013; Newport et al. 2015; Pawlosky et al.
- 74 2020); stabilized brain networks, thereby protecting the hypometabolic, aging brain (Mujica-Parodi
- et al. 2020); and decreased appetite in healthy human volunteers (Stubbs et al. 2018). Preclinical
- studies of AUD found that exogenous ketone ester (KE) decreases alcohol withdrawal signs, similar
- to a ketogenic diet (Bornebusch et al. 2021). However, the ability of exogenous KE to cross the blood
- brain barrier and alter brain energetics in AUD has not been demonstrated.
- Here, we piloted the pharmacokinetic effects of a single dose of KE on brain energetics, measured
- with either positron emission tomography (PET) with 18F-Fluoro-deoxyglucose (18F-FDG) or
- 81 proton magnetic resonance spectroscopy (1H-MRS) in individuals with AUD. All participants
- 82 underwent two imaging sessions, once after KE intervention and once without KE (baseline). We
- chose the anterior cingulate cortex (dACC) as the main region of interest for 1H-MRS because
- previous studies have evidenced a role for the dACC in inhibitory control (Gan et al. 2014), alcohol
- craving (Bauer et al. 2013), and decision making (Acheson et al. 2009) and associated aberrations in
- the dACC with subsequent worsening of problems with alcohol (Cheetham et al. 2014; Zakiniaeiz et
- 87 al. 2017). Furthermore, our previous research showed significant effects of a ketogenic diet on brain
- 88 ketone and glutamate metabolism and functional reactivity to alcohol cues in the dACC (Li et al.
- 89 2022; Wiers et al. 2021). We hypothesized that a single dose of KE would increase BHB levels in the
- brain and decrease the cerebral metabolic rate of glucose (CMRglc). For **Original Research**

- 91 Articles, Clinical Trial Articles, and Technology Reports the introduction should be succinct, with
- 92 no subheadings. For Case Reports the Introduction should include symptoms at presentation,
- 93 physical exams and lab results.

94 2 **Methods**

95

2.1 Participants and ketone ester intervention

- 96 Study participants were recruited for study protocol NCT04616781 or NCT05015881 via online
- 97 advertisements (BuildClinical, iConnect) and underwent the following screening assessment: Mini
- 98 International Neuropsychiatric Interview (MINI) for a DSM-5 diagnosis of AUD and other
- 99 neuropsychiatric disorders (1), a 30-day Timeline Follow-back (TLFB) for daily drinking patterns (2),
- 100 the Alcohol Use Disorders Identification Test (AUDIT) for hazardous drinking behavior (3), and the
- Shipley Institute of Living Scale-2 (Shipley-2) test for crystallized and fluid intelligence (4). Inclusion 101
- 102 criteria included: 1) meeting DSM-5 criteria for current AUD; 2) self-report of an average of at least
- 103 15 standard drinks per week in the last month; 3) self-report of having greater than a 1-yr history of
- 104 heavy drinking; 4) having had a drink within 1 week of the study visit. Exclusion criteria included: 1)
- 105 a current DSM-5 diagnosis of a major psychiatric disorder other than AUD; 2) intake of psychoactive
- 106
- medication within 24 hours of study participation; 3) history of seizures; 4) HIV seropositivity; 5) a 107 history of head trauma with loss of consciousness for more than 30 min or associated skull
- 108
- fracture/abnormal MRI; 6) any contraindication for MRI (e.g., presence of ferromagnetic objects or 109 claustrophobia), 7) a current, clinically significant physical disease or abnormality detected by medical
- 110 history, physical examination, or routine laboratory evaluation that can impact brain function. A
- 111 medical history and physical examination by a physician and routine laboratory results evaluated by a
- 112 physician were conducted prior to study inclusion. Five AUD participants completed the MRI study (2
- 113 females/3 males; 45.2 ± 17.0 years old), and four AUD participants completed the ¹⁸F-FDG procedures
- 114 (4 males; 31±10 years old) (**Table 1**). Two study participants were enrolled in both studies. The study
- 115 protocols were approved by the University of Pennsylvania Institutional Review Board and all
- 116 participants provided written informed consent before study participation.
- Both study protocols used a cross-over design, in which a computer-generated randomization scheme 117
- 118 assigned 50% of subjects to start with KE and 50% without KE on study visit 1, and the reverse on
- 119 visit 2. On the active day, KE ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate KE solution, TdeltaS Global
- 120 Inc.) was provided to participants at a dose of 395 mg/kg (2.2 mmol/kg) body weight.
- Participants in the MRI study were asked to fast overnight and consumed a low-calorie breakfast 121
- 122 approximately 2 hours before the scan. Participants were blinded to the study intervention and, during
- 123 the baseline visit, received an isocaloric dextrose placebo (baseline) that was taste-matched using a
- 124 bitterness additive (Symrise, US). The study drinks were prepared by the Penn Investigational Drug
- 125 Service and provided to the participants 15 minutes prior to the MRI scan or approximately 45 minutes
- prior to the ¹H-MRS scan. 126

131

- Participants in the PET ¹⁸F-FDG study fasted for at least 6 hours prior to the study, as per standard ¹⁸F-127
- 128 FDG study protocols. Participants were aware of the study intervention. KE was diluted with diet soda
- 129 or sparkling water by a trained staff member and administered to participants 1 hr prior to the PET
- 130 scan. No intervention was provided on baseline (no KE) days.

2.2 Blood measures of ketones and glucose

- Blood BHB and glucose levels were obtained from individuals participating in the PET ¹⁸F-FDG study.
- Blood BHB and glucose were measured at arrival, immediately prior to ¹⁸F-FDG injection, and 30 and
- 134 60 min post injection. On KE days, these measures corresponded with the time prior to KE intake, and
- 135 60 (immediately prior to scan), 90, and 120 min following KE intake. Measurements were made using
- a ketone and glucose meter (Abbott, Precision Xtra).

2.3 Brain ¹H-MRS imaging and processing

137

165

- 138 Participants underwent an MRI on a 3.0T Magnetom Prisma scanner (Siemens Medical Solutions USA
- 139 Inc., Malvern, PA) equipped with a 64-channel head coil. Structural images were acquired using T₁-
- weighted magnetization prepared rapid-acquisition gradient-echo (MPRAGE) sequences with the
- following parameters: TR 2400 ms; TE 2.24 ms; TI 1060 ms; FOV 256 mm; 208 slices; slice thickness
- 142 0.8 mm; flip angle 9°; effective voxel resolution, 0.8 x 0.8 x 0.8 mm.
- Localized proton magnetic resonance spectroscopy (¹H-MRS) was performed in a region of interest
- 144 (ROI) located in the dACC (40×30×15mm), for which we previously demonstrated a sensitivity to
- ketones (5, 6). A semi-Laser (sLaser) spectral editing sequence for BHB was acquired, using an adapted
- sequence previously described (7). The parameters were as follows: TR 2000 ms; TE 72 ms; 256
- averages; Editing was performed with a gaussian pulse of 18.5 ms, amplitude of 47 Hz, and a bandwith
- of 80 Hz at FWHM. For edit on, the pulse was centered at 4.14 ppm while for edit-off scans, it was
- 149 centered at 5.26 ppm relative to a water position of 4.70 ppm. First- and second-order shimming was
- 149 centered at 3.20 ppin relative to a water position of 4.70 ppin. Phys. and second-order simining was
- used to maximize the magnetic field B₀ homogeneity in the voxel. Spectral fitting of the ¹H-MRS
- datasets was carried with in-house written fitting software in IDL (NV5Geospatial, Broomfield, CO,
- USA) (8) with a modified basis set for the specific editing sequence and for ketone bodies (9). The
- basis set was simulated using GAMMA, part of the VESPA package (soher). The results from the
- analysis were inspected for nonrandom residuals and baseline fitting. Spectra with signal-to-noise ratio
- 155 (SNR) < 15 and linewidth > 0.1 ppm were excluded from further analyses. A Cramér–Rao lower bound
- 156 (CRLBs) of 20% for each individual peak was used as a quality criterion (8). To place the voxel in the
- 157 same dACC ROI during the second scan, the program ImScribe
- 158 (https://www.med.upenn.edu/CAMIPM/imscribe.html) was used, which is designed to allow
- reproducible selection of the same anatomical ROI in Siemens MRI studies within the same subject
- over multiple MRI scans. ImScribe uses high-resolution T₁-weighted images and the spectroscopy
- voxel information from the first scan as target template and T₁-weighted images of the subsequent scan
- and perform affine coregistration that provides the information of the new spectroscopic voxel
- placement for the later scans (10, 11). This was completed (~2 minutes) and this ROI was transferred
- to the Siemen's console as a DICOM image and used to prescribe the ¹H-MRS acquisition.

2.4 ¹⁸F-FDG PET scanning and processing

- On two separate study days participants underwent a 60-min ¹⁸F-FDG PET/CT scan using the PennPET
- Explorer (12), a 140 cm axial field of view whole-body PET scanner. Venous catheters were placed in
- 168 the antecubital vein bilaterally for radiotracer injection and blood sampling. Commercially
- manufactured ¹⁸F-FDG (~10 mCi) was injected intravenously over a period of approximately 1 min.
- During the PET imaging procedures, the subjects rested quietly under dim illumination and minimal
- acoustic noise. To ensure that subjects did not fall asleep, they were monitored throughout the
- procedure and were asked to keep their eyes open.
- 173 Dynamic PET images were reconstructed into 4-mm voxels using time-of-flight list-mode ordered-
- subsets expectation maximization into 39 frames: 12 x 5 s, 6 x 10 s, 3 x 20 s, 2 x 30 s, 6 x 60 s, and 10

- 175 x 300 s. Images were corrected for interframe motion and analyzed in PMOD v3.7 (PMOD
- 176 Technologies, Zurich, Switzerland). Whole brain and voxel-wise flux (K) were computed using Patlak
- graphical modeling (13) and an image-derived aortic arch blood pool SUV_{peak} input function with a
- plasma:whole blood ratio of 1:1. Measured ¹⁸F-FDG flux was converted to glucose metabolism using
- the formula MR_{Glc} = K*PG/LC, where PG is the averaged plasma glucose levels from pre-injection,
- 180 30-min, and 60-min post-injection samples, and LC is a lumped constant of 0.8 (14). The cerebral
- metabolic rate for glucose consumption (CMRglc) maps in µmol/100 mL/min were aligned to the
- subject's structural MRI and then normalized to the MNI template with a 2-mm isotropic resolution
- using the FSL Software Library (version 5.0; http://www.fmrib.ox.ac.uk/fsl)(15).

2.5 Statistical analyses

184

196

206

- All statistical analyses were conducted using SPSS (IBM, Armonk, NY). We performed linear mixed-
- effects analysis to examine the effects of the intervention (KE vs. baseline), time (assessment time
- points), and time x intervention interaction on blood measures of BHB and glucose. The models also
- 188 controlled for visit order (KE at the first or second visit) and included subject-specific random
- intercepts. *Post hoc* pairwise comparisons were performed with Bonferroni correction. Paired t-tests
- 190 were used to compare cingulate BHB and whole-brain CMRglc between KE and baseline study
- conditions. Exploratory voxel-wise FDG comparisons between KE vs baseline were performed using
- a paired t-test in SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) with a cluster-defining threshold of
- uncorrected p<0.0001 and cluster size k>50, and cluster-level threshold of familywise error (FEW)-
- 194 corrected p<0.05.

195 **3 Results**

3.1 Blood levels of ketones and glucose

- BHB levels were significantly higher following KE than baseline (Intervention: F_{1,19,3}=236, p<0.001;
- Intervention x time: $F_{3,19.3}=36$, p<0.001) and they changed with time ($F_{1,19.3}=39$, p<0.001). Post hoc
- analysis showed significant differences in BHB levels between baseline and KE at 60-, 90-, and 120-
- 200 min post-KE administration. KE increased blood BHB levels approximately 27 fold from a pre-KE
- level of 0.15mM \pm 0.12SD to 4.06 mM \pm 0.42SD 120 min following administration (**Figure 1A**).
- Blood glucose levels were lower during the KE intervention than baseline (Intervention: F_{1,19}=31,
- p<0.001) and changed with time ($F_{1,19}=12$, p<0.001), but no time x intervention interaction effects
- were observed (F_{3,19.0}=1, p=0.4) (**Figure 1B**). Post hoc analysis showed lower blood glucose levels
- between the intervention arms prior to KE administration.

2.2 Brain BHB and CMRglc

- 207 BHB levels in the dACC were significantly higher 45 min after KE intake (mean=0.83 ±0.13 mM)
- 208 than baseline visit (mean=0.28 \pm 0.11 mM) (t₄=13.4, p<0.001), as measured with ¹H-MRS in 5 AUD
- 209 participants (Figure 2A).
- Whole-brain CMRglc decreased by 17% with KE (mean CMRglc = 14.4 μ mol/100g/min \pm 1.5SD) vs.
- baseline (mean = $17.4 \pm 2.3 \mu \text{mol}/100 \text{g/min}$) (t₃=5.7, p=0.01) in 4 AUD participants (**Figure 2B**).
- 212 An exploratory voxel-wise analysis indicated that the largest KE-induced CMRglc reductions were in
- 213 the frontal cortex, including the bilateral inferior frontal gyrus (IFG), occipital cortex, parietal and

- 214 temporal lobe, anterior cingulate cortex, bilateral amygdalae, hippocampi and insulae (all pfwe<0.05)
- 215 (Figure 2B. Table 2).

Discussion

- 217 We found that a single dose of the KE (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (TdeltaS Global Inc.)
- 218 rapidly elevated blood ketone levels and shifted brain energetics from glucose to ketones in individuals
- 219 with AUD. While blood BHB remained low (~0.2 mM) through the baseline visit, it increased to 3.2
- 220 mM within 1 hr of KE administration and to 4.1 mM after 2 hr. Quantification of brain BHB levels and
- 221 glucose utilization with ¹H-MRS and PET, respectively, showed higher dACC BHB levels and lower
- 222 whole-brain glucose metabolism following KE administration compared to baseline in individuals with
- 223 AUD.

- 224 Glucose is the primary fuel for the brain and is necessary for normal neural functioning, including
- 225 maintaining a resting potential, generating an action potential, and synthesizing neurotransmitters and
- 226 neuromodulators (16, 17). Ketone bodies are produced endogenously in the liver during periods in
- 227 which glucose is not readily available, such as when an individual is adherent to a high-fat, low-
- 228 carbohydrate ketogenic diet. They are carried through the bloodstream and transported into neurons by
- 229 monocarboxylate transporters, where they are utilized for fuel (18). Exogenous KE supplements
- 230 provide a faster, less dietary restrictive alternative to a ketogenic diet to achieve nutritional ketosis (19-
- 231 21). As demonstrated in our study, within 1-2 hr of administration KE elevated blood BHB levels
- 232 similar to those seen following 1-2 wk of adherence to a ketogenic diet (5). Similar blood BHB levels
- 233 have previously been reported with the same dose of KE (19). Localized ¹H-MRS provides a non-
- 234 invasive method to measure ketone levels in the brains of individuals adhering to a ketogenic diet (9,
- 235 22). We found rapid and efficient brain uptake of BHB following KE administration and demonstrated
- 236 significantly higher BHB levels in the dACC during the KE session than the baseline session.
- 237
- Furthermore, KE yielded lower blood glucose levels, which may be due to a small KE-induced increase
- in insulin levels (19, 23). Moreover, we found an average 17% reduction in CMRglc from baseline to 238
- 239 KE, which is comparable to that previously observed following 4 days of a ketogenic diet intervention
- 240 (24). It is important to note that reductions in CMRglc have been found to be proportionate to plasma
- 241 BHB levels (25), and not to hypoglycemia per se (24). In contrast, plasma levels of glucose correlate
- 242 inversely with brain glucose metabolism and hyperglycemia has been associated with significantly
- 243 lower brain glucose metabolism (26). Thus, our findings are in line with previous reports that CMRglc
- 244 is inversely associated with blood and brain ketone levels (24), and thus that when plasma ketones
- 245 increase, the human brain meets its metabolic needs by reducing CMRglc in relation to ketone
- 246 availability and uptake.
- 247 Emerging evidence attributes heavy alcohol consumption and AUD to deficiencies in brain energy
- metabolism (18, 27). Acetate is a byproduct of alcohol metabolism and produces energy through 248
- 249 conversion to acetyl-coenzyme A and metabolism in the tricarboxylic acid (TCA) cycle (28). Alcohol
- 250 intoxication acutely increases plasma levels of acetate, brain uptake of acetate, and decreases brain
- 251 glucose utilization (27, 29). Chronic use of alcohol produces metabolic adaptations that exacerbate this
- 252 shift in brain energetics and increase the brain's reliance on acetate for energy (27, 30). Similarly, gene
- 253 and protein analysis from rodents and post-mortem human brain tissues show a reduction in glucose
- 254 metabolism pathways (i.e., glycolysis and gluconeogenesis) and increased expression of
- 255 monocarboxylated transporters after chronic alcohol use (31, 32). It has been hypothesized that
- 256 deprivation of acetate as an energy source and inability to abruptly transition to utilizing glucose during
- abstinence contribute to alcohol withdrawal signs and symptoms and alcohol craving in individuals 257
- 258 undergoing detoxication (18, 27). Heavy drinkers also demonstrated higher levels of ¹³C-labeled brain
- 259 acetate than light drinkers (33). Ketone bodies are similar to acetate in that they also are converted to

acetyl-coenzyme A and produce energy in the TCA cycle. Targeting brain energetics with a ketogenic dietary intervention was previously shown to increase blood and brain ketone levels and attenuate withdrawal signs and symptoms and alcohol craving in individuals with AUD who were undergoing alcohol detoxification treatment (5). Here we demonstrated that KE rapidly increases blood and brain

BHB levels and reduces the need for brain glucose utilization in individuals with AUD, and may thus

serve as a more palatable alternative to a ketogenic dietary intervention in treating individuals with AUD.

Our study has several limitations and identifies potential areas for future study. First, although we employed a cross-over design to mitigate potential confounding effects of inter-individual differences, the study sample is small. Second, our sample was limited to individuals with AUD. It has been well demonstrated that individuals with AUD have lower brain glucose metabolism than non-dependent healthy controls (27, 34, 35). Moreover, alcohol-induced increases in acetate metabolism correlate with alcohol drinking history and were greater in heavy drinkers than social drinkers, suggesting that heavy or chronic alcohol exposure facilitates the use of acetate as a brain energy substrate (30). Thus, future studies are needed to compare KE-induced increases in BHB levels and reductions in CMRglc between individuals with AUD and non-dependent volunteers, to ascertain whether KE-induced elevations in ketones and reductions in CMRglc are greater among individuals who are very heavy alcohol consumers. Third, ¹H-MRS cannot differentiate between intracellular and extracellular levels of BHB and is thus limited in assessing BHB utilization in the brain. Fourth, post hoc pairwise analysis showed lower blood glucose in the KE treatment arm compared to the baseline visit prior to KE administration, which may have been confounding. However, all CMRglc analyses were corrected for blood glucose level, and likely did not affect the strong KE-induced reductions in CMRglc. Indeed, previous studies reported an inverse relationship between blood and brain glucose, such that higher brain glucose uptake was seen in individuals with lower blood glucose levels (26, 36, 37). Therefore, our findings of decreased brain glucose uptake with KE despite lower blood glucose levels supports the robust effect of KE in altering brain energetics. Last, the implications of KE-induced changes in brain energetics on clinical outcomes in AUD are unknown. To address this gap in the literature, we plan to conduct studies

288 In sum, our findings provide the first evidence that KE administration rapidly shifts brain energetics

that examine the effects of KE on alcohol withdrawal and alcohol craving in individuals with AUD.

- 289 from glucose to ketone metabolism in individuals with AUD. Understanding the neurometabolic
- 290 effects of KE may provide a scientific basis for studies examining the feasibility of utilizing KE as a
- 291 treatment option for AUD or other neuropsychiatric and neurological disorders. Such findings may
- also help to identify potential neural mechanisms for these clinical effects.

5 Author Contributions

- 294 CEW designed the study. XL, JB, SV, RR, TP, ME, RR, HK, RPRN, JGD collected the data. AY,
- LSP, RKD, RR, RPRN, JVDV, CEW, and ZS analyzed the data and interpreted the results. XL, ZS,
- 296 HK, AY, RPRN, and CEW wrote the manuscript. All authors provided critical revision of the
- 297 manuscript for intellectual content and approved the final version of the manuscript.

298 6 Funding

264

267

268

269

270

271

272273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

- 299 This work was supported by the Institute for Translational Medicine and Therapeutics' (ITMAT)
- 300 Transdisciplinary Program in Translational Medicine and Therapeutics (Wiers & Dubroff), a
- NARSAD Young Investigator Grant (28778, Wiers), and the following National Institutes of Health
- 302 grants: AA026892 (Wiers), DA051709 (Shi), DA046345 (Kranzler), and and P41 EB029460 (Reddy).
- 303 Dr. Li was supported by T32DA028874.

7 Acknowledgments

304

- We thank Laurie Downing, Kim Olson, Klaudia Glogowska, Rachel Weyl, Erin Schubert, Matt Furey,
- Regan Scheffer, Kayla Spooner, Reagan Wetherill, Nora Volkow, Paco Bravo, Aiden Adams, David
- 307 Mankoff, Robert Mach, and the Penn PET Center for their contributions.

308 **8** Conflict of Interest

- 309 The authors declare that the research was conducted in the absence of any commercial or financial
- relationships that could be construed as a potential conflict of interest.

311 9 Data Availability Statement

- The data that support the findings of this study are available from the corresponding author upon
- 313 reasonable request.

10 References

- 315 1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-
- 316 International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured
- diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-
- 318 33;quiz 4-57.
- 319 2. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported alcohol
- 320 consumption. Measuring alcohol consumption: Psychosocial and biochemical methods. Totowa, NJ,
- 321 US: Humana Press/Springer Nature; 1992. p. 41-72.
- 322 3. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol
- 323 Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of
- Persons with Harmful Alcohol Consumption--II. Addiction. 1993;88(6):791-804.
- 325 4. Zachary RA, Paulson MJ, Gorsuch RL. Estimating WAIS IQ from the Shipley Institute of
- Living Scale using continuously adjusted age norms. J Clin Psychol. 1985;41(6):820-31.
- 327 5. Wiers CE, Vendruscolo LF, van der Veen J-W, Manza P, Shokri-Kojori E, Kroll DS, et al.
- 328 Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents.
- 329 Science Advances. 2021;7(15):eabf6780.
- 330 6. Li X, Shi Z, Byanyima J, Morgan PT, van der Veen JW, Zhang R, et al. Brain glutamate and
- 331 sleep efficiency associations following a ketogenic diet intervention in individuals with Alcohol Use
- 332 Disorder. Drug Alcohol Depend Rep. 2022;5.
- 333 7. Landheer K, Gajdošík M, Juchem C. A semi-LASER, single-voxel spectroscopic sequence
- with a minimal echo time of 20.1 ms in the human brain at 3 T. NMR Biomed. 2020;33(9):e4324.
- 335 8. van der Veen JW, Marenco S, Berman KF, Shen J. Retrospective correction of frequency drift
- in spectral editing: The GABA editing example. NMR Biomed. 2017;30(8).
- 337 9. Cecil KM, Mulkey SB, Ou X, Glasier CM. Brain ketones detected by proton magnetic
- resonance spectroscopy in an infant with Ohtahara syndrome treated with ketogenic diet. Pediatr
- 339 Radiol. 2015;45(1):133-7.
- 340 10. Wolf DH, Satterthwaite TD, Loughead J, Pinkham A, Overton E, Elliott MA, et al. Amygdala
- abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine
- 342 challenge. Psychopharmacology (Berl). 2011;218(3):503-12.
- Nanga RP, Hariharan H, Reddy R. Fully automated macromolecule suppressed single voxel
- 344 glutamate spectroscopy (FAMOUS SVGS). J Transl Med. 2016;14(1):220.

- 345 12. Dai B, Daube-Witherspoon ME, McDonald S, Werner ME, Parma MJ, Geagan MJ, et al.
- Performance evaluation of the PennPET explorer with expanded axial coverage. Phys Med Biol.
- 347 2023;68(9).
- 348 13. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer
- constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1-7.
- 350 14. Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, et al. A cross-sectional
- comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild
- 352 cognitive impairment and early Alzheimer's disease. Exp Gerontol. 2018;107:18-26.
- 353 15. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al.
- 354 Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage.
- 355 2004;23 Suppl 1:S208-19.
- 356 16. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J
- 357 Cereb Blood Flow Metab. 2001;21(10):1133-45.
- 358 17. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in
- physiological and pathological brain function. Trends Neurosci. 2013;36(10):587-97.
- 360 18. Mahajan VR, Elvig SK, Vendruscolo LF, Koob GF, Darcey VL, King MT, et al. Nutritional
- 361 Ketosis as a Potential Treatment for Alcohol Use Disorder. Front Psychiatry. 2021;12:781668.
- 362 19. Stubbs BJ, Cox PJ, Evans RD, Cyranka M, Clarke K, de Wet H. A Ketone Ester Drink
- Lowers Human Ghrelin and Appetite. Obesity. 2018;26(2):269-73.
- 364 20. Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, et al. On the Metabolism of
- Exogenous Ketones in Humans. Front Physiol. 2017;8:848.
- 366 21. Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. Diet modulates
- brain network stability, a biomarker for brain aging, in young adults. Proceedings of the National
- Academy of Sciences of the United States of America. 2020;117(11):6170-7.
- 369 22. Wright JN, Saneto RP, Friedman SD. β-Hydroxybutyrate Detection with Proton MR
- 370 Spectroscopy in Children with Drug-Resistant Epilepsy on the Ketogenic Diet. AJNR Am J
- 371 Neuroradiol. 2018;39(7):1336-40.
- 372 23. Veech RL, Bradshaw PC, Clarke K, Curtis W, Pawlosky R, King MT. Ketone bodies mimic
- the life span extending properties of caloric restriction. IUBMB Life. 2017;69(5):305-14.
- 24. Courchesne-Loyer A, Croteau E, Castellano CA, St-Pierre V, Hennebelle M, Cunnane SC.
- 375 Inverse relationship between brain glucose and ketone metabolism in adults during short-term
- 376 moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb
- 377 Blood Flow Metab. 2017;37(7):2485-93.
- 378 25. Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, et al. Changes in
- 379 cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. The American
- 380 journal of physiology. 1996;270(5 Pt 1):E746-51.
- 381 26. Sarikaya I, Albatineh AN, Sarikayaa A. Effect of various blood glucose levels on regional
- FDG uptake in the brain. Asia Ocean J Nucl Med Biol. 2020;8(1):46-53.
- Volkow ND, Wiers CE, Shokri-Kojori E, Tomasi D, Wang GJ, Baler R. Neurochemical and
- metabolic effects of acute and chronic alcohol in the human brain: Studies with positron emission
- tomography. Neuropharmacology. 2017;122:175-88.
- 386 28. Bose S, Ramesh V, Locasale JW. Acetate Metabolism in Physiology, Cancer, and Beyond.
- 387 Trends Cell Biol. 2019;29(9):695-703.
- Volkow ND, Wang GJ, Franceschi D, Fowler JS, Thanos PP, Maynard L, et al. Low doses of
- alcohol substantially decrease glucose metabolism in the human brain. Neuroimage. 2006;29(1):295-
- 390 301.
- 391 30. Volkow ND, Kim SW, Wang G-J, Alexoff D, Logan J, Muench L, et al. Acute alcohol
- intoxication decreases glucose metabolism but increases acetate uptake in the human brain.
- 393 NeuroImage. 2013;64:277-83.

- 394 31. Bhat UA, Kumar SA, Chakravarty S, Patel AB, Kumar A. Differential Effects of Chronic
- 395 Ethanol Use on Mouse Neuronal and Astroglial Metabolic Activity. Neurochemical Research.
- 396 2023;48(8):2580-94.
- 397 32. Enculescu C, Kerr ED, Yeo KYB, Schenk G, Fortes MRS, Schulz BL. Proteomics Reveals
- 398 Profound Metabolic Changes in the Alcohol Use Disorder Brain. ACS Chem Neurosci.
- 399 2019;10(5):2364-73.
- 400 33. Jiang L, Gulanski BI, De Feyter HM, Weinzimer SA, Pittman B, Guidone E, et al. Increased
- brain uptake and oxidation of acetate in heavy drinkers. J Clin Invest. 2013;123(4):1605-14.
- 402 34. Tomasi DG, Wiers CE, Shokri-Kojori E, Zehra A, Ramirez V, Freeman C, et al. Association
- 403 Between Reduced Brain Glucose Metabolism and Cortical Thickness in Alcoholics: Evidence of
- Neurotoxicity. The international journal of neuropsychopharmacology / official scientific journal of
- 405 the Collegium Internationale Neuropsychopharmacologicum. 2019;22(9):548-59.
- Wiers CE, Cabrera E, Skarda E, Volkow ND, Wang GJ. PET imaging for addiction medicine:
- 407 From neural mechanisms to clinical considerations. Progress in brain research. 2016;224:175-201.
- 408 36. Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E, et al. Effects of blood
- 409 glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an
- 410 analysis on 5623 patients. Sci Rep. 2018;8(1):2126.
- 411 37. Sarikaya I, Sarikaya A, Sharma P. Assessing the Effect of Various Blood Glucose Levels on
- 412 (18)F-FDG Activity in the Brain, Liver, and Blood Pool. J Nucl Med Technol. 2019;47(4):313-8.

11 Figure legends

413

414

419

428

429

430

- Figure 1. Blood ketone and glucose levels with Ketone Ester (KE). (A) Blood ketone (BHB) levels
- increased 27x with KE (mean baseline = 0.15 mM \pm 0.12, KS=4.06 mM \pm 0.42, Intervention x Time:
- $F_{3,6}=31.37$, p<0.001). (**B**) There was no Intervention x Time effect for glucose levels, but significant
- 418 main effects of Intervention $(F_{1,19}=31, p<0.001)$ and Time $(F_{1,19}=12, p<0.001)$.
- 420 Figure 2. Brain pharmacokinetics of Ketone Ester (KE). (A) Beta-hydroxybutyrate (BHB) levels
- in the anterior cingulate cortex were significantly higher 45 min after KE intake (mean=0.83±0.13)
- than at the baseline visit (mean=0.28±0.11) as measured with ¹H-MRS in 5 AUD participants. (B)
- Whole-brain metabolic rate of glucose (CMRglc) decreased significantly with KE (mean CMRglc=
- 424 $14.4\pm1.5 \, \mu \text{mol}/100 \text{g/min}$) vs. baseline (mean=17.4±2.3 $\mu \text{mol}/100 \text{g/min}$) in 4 AUD participants.
- 425 Average whole-brain CMRglc shows the strongest effects of KE in lowering brain glucose metabolism
- 426 in the frontal cortex, occipital cortex, temporal cortex, and anterior cingulate (all p < 0.05). *p < 0.05
- 427 ****p* < 0.001.

12 Tables

Table 1. Demographics and clinical characteristics of the participants in the ${}^{1}\text{H-MRS}$ and ${}^{18}\text{F-}$ FDG PET studies. Data are presented as mean \pm SD

Characteristic	MRI study (n=5)	FDG study (n=4)	
Sex at birth	2 females/ 3 males	4 males	
Age (years)	45.2 ± 17.0	31 ± 10	
Race	3 African American/ 2	2 African American/ 2	
	Caucasian	Caucasian	

BMI (kg/m ²)	26.3 ± 5.3	30.6 ±2.7	_
Shipley IQ score	106.6 ± 7.2	106.5 ± 20.0	
Drinks/week	28.3 ± 10.1	27.2 ± 3.0	
AUDIT	17.4 ± 6.8	15.0 ± 4.8	

Abbreviation: AUDIT, Alcohol Use Disorders Identification Test; BMI, Body-Mass Index

Table 2. Brain regions showing a significant main effect of Intervention.

Brain Region	Cluster size (mm³)	Z	MNI coordinates
KE < Baseline			_
Frontal cortex, IFG, Precentral gyrus	199	5.32	62, 2, 36
Frontal cortex, IFG, Precentral gyrus, Insula	8449	5.18	-46, -12, 28
Precuneus, Parietal lobe	524	4.98	-24, -60, 42
Occipital cortex, Fusiform gyrus, Temporal lobe	4019	4.93	60, -70, 24
Anterior Cingulate, dACC, Posterior Cingulate	1300	4.53	-8, 14, 26
Insula	207	4.22	40, 0, 16
Brainstem, Pons	798	4.21	10, -16, -34
Amygdala, Hippocampus	332	4.19	-24, -4, -24
Superior frontal gyrus	174??	4.18	-14, 22, 58
Amygdala, Hippocampus	193	3.86	38, 0, -20
Precentral, Middle frontal gyrus	238	3.81	38, -12, 60
Precuneus, Parietal lobe	399	3.79	30, -56, 48

Baseline < KE

431 432 433

434435

No significant clusters

Abbreviations: dACC, dorsal Anterior Cingulate Cortex, IFG Inferior Frontal Gyrus, MNI, Montreal Neurological Institute